Amphastar Pharmaceuticals (AMPH) Competitors

$17.20 +0.33 (+1.96%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$16.77 -0.43 (-2.52%)

As of 07:20 AM Eastern

AMPH vs. TVTX, EWTX, ACAD, CPRX, and TLX

Should you buy Amphastar Pharmaceuticals stock or one of its competitors? MarketBeat compares Amphastar Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amphastar Pharmaceuticals include Travere Therapeutics (TVTX), Edgewise Therapeutics (EWTX), ACADIA Pharmaceuticals (ACAD), Catalyst Pharmaceuticals (CPRX), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry.

How does Amphastar Pharmaceuticals compare to Travere Therapeutics?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 8 mentions for Amphastar Pharmaceuticals and 5 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.19 beat Amphastar Pharmaceuticals' score of 0.05 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Travere Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Travere Therapeutics' net margin of -4.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

Amphastar Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Amphastar Pharmaceuticals has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.05	$98.09M	$1.66	10.36
Travere Therapeutics	$490.73M	8.13	-$25.55M	-$0.23	N/A

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Amphastar Pharmaceuticals presently has a consensus target price of $24.50, suggesting a potential upside of 42.44%. Travere Therapeutics has a consensus target price of $47.83, suggesting a potential upside of 11.53%. Given Amphastar Pharmaceuticals' higher probable upside, equities research analysts plainly believe Amphastar Pharmaceuticals is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Amphastar Pharmaceuticals beats Travere Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

In the previous week, Amphastar Pharmaceuticals had 5 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 8 mentions for Amphastar Pharmaceuticals and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.65 beat Amphastar Pharmaceuticals' score of 0.05 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Edgewise Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Edgewise Therapeutics presently has a consensus price target of $39.67, suggesting a potential upside of 25.05%. Amphastar Pharmaceuticals has a consensus price target of $24.50, suggesting a potential upside of 42.44%. Given Amphastar Pharmaceuticals' higher probable upside, analysts clearly believe Amphastar Pharmaceuticals is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Edgewise Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

Amphastar Pharmaceuticals has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
Amphastar Pharmaceuticals	$719.89M	1.05	$98.09M	$1.66	10.36

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 23.2% of Edgewise Therapeutics shares are held by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Amphastar Pharmaceuticals beats Edgewise Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to ACADIA Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

In the previous week, Amphastar Pharmaceuticals had 1 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 8 mentions for Amphastar Pharmaceuticals and 7 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.57 beat Amphastar Pharmaceuticals' score of 0.05 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amphastar Pharmaceuticals presently has a consensus price target of $24.50, indicating a potential upside of 42.44%. ACADIA Pharmaceuticals has a consensus price target of $31.18, indicating a potential upside of 50.68%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Amphastar Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Amphastar Pharmaceuticals' net margin of 11.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

ACADIA Pharmaceuticals has higher revenue and earnings than Amphastar Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.05	$98.09M	$1.66	10.36
ACADIA Pharmaceuticals	$1.07B	3.31	$391M	$2.20	9.40

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

ACADIA Pharmaceuticals beats Amphastar Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Amphastar Pharmaceuticals' net margin of 11.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Amphastar Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

Catalyst Pharmaceuticals has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Catalyst Pharmaceuticals presently has a consensus price target of $32.17, indicating a potential upside of 3.00%. Amphastar Pharmaceuticals has a consensus price target of $24.50, indicating a potential upside of 42.44%. Given Amphastar Pharmaceuticals' higher possible upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	3 Strong Buy rating(s)	2.88
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

In the previous week, Amphastar Pharmaceuticals had 6 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 8 mentions for Amphastar Pharmaceuticals and 2 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 0.61 beat Amphastar Pharmaceuticals' score of 0.05 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Catalyst Pharmaceuticals has higher earnings, but lower revenue than Amphastar Pharmaceuticals. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99M	6.49	$214.33M	$1.74	17.95
Amphastar Pharmaceuticals	$719.89M	1.05	$98.09M	$1.66	10.36

Summary

Catalyst Pharmaceuticals beats Amphastar Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Telix Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Amphastar Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

In the previous week, Amphastar Pharmaceuticals had 4 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 8 mentions for Amphastar Pharmaceuticals and 4 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.62 beat Amphastar Pharmaceuticals' score of 0.05 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Telix Pharmaceuticals' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Telix Pharmaceuticals	N/A	N/A	N/A

Amphastar Pharmaceuticals presently has a consensus price target of $24.50, indicating a potential upside of 42.44%. Telix Pharmaceuticals has a consensus price target of $21.13, indicating a potential upside of 105.50%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Amphastar Pharmaceuticals has higher earnings, but lower revenue than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.05	$98.09M	$1.66	10.36
Telix Pharmaceuticals	$803.79M	4.34	-$7.12M	N/A	N/A

Summary

Amphastar Pharmaceuticals beats Telix Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Amphastar Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMPH vs. The Competition

Export

Metric	Amphastar Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$743.85M	$5.87B	$6.25B	$12.29B
Dividend Yield	N/A	0.68%	2.80%	5.32%
P/E Ratio	10.36	8.49	20.64	25.23
Price / Sales	1.05	20.38	554.85	79.36
Price / Cash	3.96	8.55	27.48	37.30
Price / Book	1.00	3.92	9.66	6.63
Net Income	$98.09M	$102.24M	$3.56B	$335.59M
7 Day Performance	-1.71%	-2.00%	-1.65%	-1.20%
1 Month Performance	-24.83%	-6.07%	-2.60%	-1.16%
1 Year Performance	-30.62%	115.19%	30.07%	28.10%

Amphastar Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMPH Amphastar Pharmaceuticals	4.1648 of 5 stars	$17.20 +2.0%	$24.50 +42.4%	-30.8%	$743.85M	$719.89M	10.36	1,976
TVTX Travere Therapeutics	1.9177 of 5 stars	$44.80 -0.2%	$46.58 +4.0%	+155.3%	$4.14B	$490.73M	N/A	460
EWTX Edgewise Therapeutics	2.5514 of 5 stars	$38.03 +20.9%	$38.13 +0.2%	+114.6%	$4.09B	N/A	N/A	60	Gap Up High Trading Volume
ACAD ACADIA Pharmaceuticals	4.4323 of 5 stars	$22.35 +0.7%	$31.21 +39.6%	-7.1%	$3.83B	$1.07B	9.76	510
CPRX Catalyst Pharmaceuticals	4.2655 of 5 stars	$30.90 +6.8%	$34.00 +10.0%	+28.1%	$3.77B	$588.99M	18.28	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMPH) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. TVTX, EWTX, ACAD, CPRX, and TLX

How does Amphastar Pharmaceuticals compare to Travere Therapeutics?

Summary

How does Amphastar Pharmaceuticals compare to Edgewise Therapeutics?

Summary

How does Amphastar Pharmaceuticals compare to ACADIA Pharmaceuticals?

Summary

How does Amphastar Pharmaceuticals compare to Catalyst Pharmaceuticals?

Summary

How does Amphastar Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. TVTX, EWTX, ACAD, CPRX, and TLX

How does Amphastar Pharmaceuticals compare to Travere Therapeutics?

Does the media favor AMPH or TVTX?

Is AMPH or TVTX more profitable?

Which has more risk & volatility, AMPH or TVTX?

Which has higher valuation & earnings, AMPH or TVTX?

Do institutionals and insiders have more ownership in AMPH or TVTX?

Do analysts prefer AMPH or TVTX?

Summary

How does Amphastar Pharmaceuticals compare to Edgewise Therapeutics?

Does the media prefer EWTX or AMPH?

Which has more risk and volatility, EWTX or AMPH?

Do analysts recommend EWTX or AMPH?

Is EWTX or AMPH more profitable?

Which has higher earnings and valuation, EWTX or AMPH?

Do institutionals and insiders have more ownership in EWTX or AMPH?

Summary

How does Amphastar Pharmaceuticals compare to ACADIA Pharmaceuticals?

Does the media refer more to AMPH or ACAD?

Do analysts rate AMPH or ACAD?

Which has more volatility and risk, AMPH or ACAD?

Is AMPH or ACAD more profitable?

Which has better valuation & earnings, AMPH or ACAD?

Do institutionals and insiders believe in AMPH or ACAD?

Summary

How does Amphastar Pharmaceuticals compare to Catalyst Pharmaceuticals?

Do insiders & institutionals believe in CPRX or AMPH?

Is CPRX or AMPH more profitable?

Which has more risk & volatility, CPRX or AMPH?

Do analysts recommend CPRX or AMPH?

Does the media refer more to CPRX or AMPH?

Which has better earnings and valuation, CPRX or AMPH?

Summary

How does Amphastar Pharmaceuticals compare to Telix Pharmaceuticals?

Which has more risk and volatility, AMPH or TLX?

Does the media favor AMPH or TLX?

Do insiders and institutionals believe in AMPH or TLX?

Is AMPH or TLX more profitable?

Do analysts recommend AMPH or TLX?

Which has better earnings and valuation, AMPH or TLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools